# Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
Canonical URL: https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-initiation-of-phase-3-harmonia-trial-of-z-basivarsen-in-myotonic-dystrophy-type-1-dm1
Ticker: DYN
Company: Dyne Therapeutics
Source: Dyne Therapeutics
Published: 2026-03-08 22:01 EST
Original Source URL: https://investors.dyne-tx.com
## Summary

- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1  - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary endpoint is the five times sit to stand (5xSTS) test; secondary and exploratory

## Article Body
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1  - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary endpoint is the five times sit to stand (5xSTS) test; secondary and exploratory
## Recent Company News
- 2026-06-03 11:30 EST — [Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)](https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-completion-of-enrollment-in-registrational-expansion-cohort-of-achieve-trial-of-z-basivarsen-for-myotonic-dystrophy-type-1-dm1) — Source: Dyne Therapeutics
- 2026-05-26 11:30 EST — [Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)](https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-submission-of-biologics-license-application-bla-to-u-s-fda-for-z-rostudirsen-in-exon-51-duchenne-muscular-dystrophy-dmd) — Source: Dyne Therapeutics
- 2026-05-20 11:46 EST — [Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval](https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-initiation-of-phase-3-forzetto-trial-of-z-rostudirsen-in-duchenne-muscular-dystrophy-dmd-ahead-of-planned-bla-submission-for-u-s-accelerated-approval) — Source: Dyne Therapeutics
- 2026-05-11 11:30 EST — [Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/DYN/dyne-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights) — Source: Dyne Therapeutics
- 2026-04-27 20:34 EST — [Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting](https://biopharmsignal.com/news/DYN/dyne-therapeutics-announces-upcoming-presentation-highlighting-robust-cns-activity-in-nonhuman-primates-with-its-forcetm-platform-at-2026-asgct-annual-meeting) — Source: Dyne Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)